Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Niacin therapy in atherosclerosis.

C Daniel Meyers¹, Vajinath S Kamanna, Moti L Kashyap

¹Endocrinology Section, VA Long Beach Healthcare System, Department of Medicine, University of California, Irvine, California, USA.

Current Opinion in Lipidology

|November 6, 2004

Summary

Niacin effectively prevents cardiovascular disease and death, even in diabetic patients. Its novel mechanisms improve lipid profiles and offer atheroprotective benefits beyond lipid lowering.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Niacin increases human aortic endothelial Sirt1 activity and nitric oxide: effect on endothelial function and vascular aging.

American journal of translational research·2024

Same author

Niacin regresses collagen content in human hepatic stellate cells from liver transplant donors with fibrotic non-alcoholic steatohepatitis (NASH).

American journal of translational research·2022

Same author

Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?

Journal of clinical lipidology·2019

Same author

Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease.

Journal of the Endocrine Society·2019

Same author

Effects of Extended-Release Niacin on Quartile Lp-PLA<sub>2</sub> Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.

Journal of cardiovascular pharmacology and therapeutics·2019

Same author

Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

The Journal of clinical endocrinology and metabolism·2019

Area of Science:

Cardiovascular Disease Research
Lipid Metabolism
Pharmacology

Background:

Niacin (nicotinic acid) is proven to prevent cardiovascular disease and death.
Historically, concerns about tolerability and contraindication in diabetes limited its use.
Renewed interest in niacin stems from evidence supporting the treatment of multiple lipid risk factors for cardiovascular risk reduction.

Purpose of the Study:

To review emerging evidence on the safety and efficacy of niacin in patients with diabetes.
To explore the novel mechanisms of action of niacin in lipid metabolism and atheroprotection.
To evaluate the role of niacin in combination therapy for cardiovascular risk reduction.

Main Methods:

Review of emerging clinical evidence and recent scientific discoveries.
Analysis of niacin's effects on lipoprotein subclasses and triglyceride synthesis.
Investigation of niacin's interaction with the nicotinic acid receptor (HM74) and nuclear transcription factors.

Main Results:

Niacin is safe and effective in diabetic patients, beneficially altering lipoprotein profiles.
Niacin inhibits hepatic triglyceride synthesis and very low-density lipoprotein secretion via diacylglycerol acyltransferase 2.
Niacin exhibits antioxidant, anti-inflammatory, and other non-lipid-lowering atheroprotective effects, potentially via HM74 and nuclear transcription factors.

Conclusions:

Niacin demonstrates novel mechanisms in lipoprotein metabolism and provides atheroprotective non-lipid benefits.
Combination therapy with niacin and agents like statins offers enhanced cardiovascular risk reduction.
Further research into niacin's mechanisms may reveal new therapeutic targets for drug development.

Related Experiment Videos